Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer. [PDF]
Zimmerman BS, Esteva FJ.
europepmc +1 more source
HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future. [PDF]
Xu L +6 more
europepmc +1 more source
Nature's carriers: leveraging extracellular vesicles for targeted drug delivery. [PDF]
Chen Q +5 more
europepmc +1 more source
Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody-Drug Conjugate Therapies. [PDF]
Major M, Nervig CS, Gerland A, Owen SC.
europepmc +1 more source
Mechanisms of resistance to antibody-drug conjugates in breast cancer. [PDF]
Cerci B, Saatci O, Basik M, Sahin O.
europepmc +1 more source
Failure to progress: breast and prostate cancer cell lines in developing targeted therapies. [PDF]
James C +4 more
europepmc +1 more source
Low level CO2 supplementation maintains isocapnia and reveals ventilatory long-term facilitation in rats. [PDF]
Miller S +3 more
europepmc +1 more source
Efficacy and safety of antibody-drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials. [PDF]
Ren JW, Chen ZY, Bai YJ, Han P.
europepmc +1 more source

